Close Menu

Ortho-McNeil, J&J to Use Cellzome Proteomics Tech in Alzheimer’s Research Program

Cellzome last week said that it will collaborate with Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Pharmaceutical, in a drug-discovery research program for Alzheimer’s disease.

Cellzome will apply its chemical proteomics technology to the program, and will receive a technology-access fee and research funding for two years. The company said it is also eligible for development milestone payments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report on a concerning strain of the H1N1 swine flu virus found among pigs in China, Agence France Presse reports.

Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.

The Associated Press reports that US officials are considering allowing pooled COVID-19 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.